PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/637,962
				Filing Date	August 11, 2000
				Confirmation Number	8001
				First Named Inventor	Lawrence H. Thompson
				Group Art Unit	1647
				Examiner Name	Regina M. Deberry
Sheet	1	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

OIPE JC158 MAR 12 2003 PATENT & TRADEMARK OFFICE

RECEIVED MAR 17 2003 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	4,703,008		Lin, F-K	10/27/1987
	2	5,688,679		Powell, J.S.	11/18/1997
	3	5,955,422		Lin, F-K	09/21/1999
	4	2002/0037832	A1	Nielsen et al.	03/28/2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office	Number[4]	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T[6]
	5	EP	0 813 877	A2	SmithKline Beecham Corporation	12/29/1997	
	6	WO	88/00241	A1	Board of Regents of the University of Washington	01/14/1988	
	7	WO	00/24893	A2	AMGEN Inc.	05/04/2000	
	8	WO	00/35475	A2	Ehrenreich, Hannelore	06/22/2000	
	9	WO	01/82952	A2	Action Pharmaceuticals APS	11/08/2001	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

paper No: 14

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/637,962
				Filing Date	August 11, 2000
				Confirmation Number	8001
				First Named Inventor	Lawrence H. Thompson
				Group Art Unit	1647
				Examiner Name	Regina M. Deberry
Sheet	2	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

OIPE MAR 1 2 2003 PATENT & TRADEMARK OFFICE

	10	WO	01/91780	A1	Ortho-McNeil Pharmaceutical, Inc.	12/06/2001	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	11	ACHARYA et al., Effect of Low Dose Recombinant Human Omega Erythropoietin (rHuEPO) on Anaemia in Patients with Hemodialysis, Journal of the Association of Physicians of India, (1995), pp. 539-542, Vol. 43:8	
	12	BIESMA, D.H., Erythropoietin Treatment for Non-Uremic Patients: A Personal View, The Netherlands Journal of Medicine, (1999), pp. 10-15, Vol. 54	
	13	BIESMA, D.H. et al., Lower Homologous Blood Requirement in Autologous Blood Donors After Treatment with Recombinant Human Erythropoietin, The Lancet, (1994), pp. 367-370, Vol. 344	
	14	BREN, A. et al., A Comparison Between Epoetin Omega and Epoetin Alfa in the Correction of Anemia in Hemodialysis Patients: A Prospective, Controlled Crossover Study, Artificial Organs, (2002), pp. 91-97, Vol. 26:2	
	15	BREN, A.F. et al., Experiences with Epoetin Omega and Epoetin Alfa in Hemodialysis Patients, J Am Soc Nephrol, A1813, (2001), p. 352A, Vol. 12	
	16	CANADIAN ERYTHROPOIETIN STUDY GROUP, Association Between Recombinant Human Erythropoietin and Quality of Life and Exercise Capacity of Patients Receiving Haemodialysis, BMJ, (1990), pp. 573-578, Vol. 300	
	17	CASTELLI, G. et al., Detection of Anti-Erythropoietin Antibodies in Haemodialysis Patients Treated with Recombinant Human-Erythropoietin, Pharmacological Research, (2000), pp. 313-318, Vol. 41:3	
	18	CHOI, D. et al., Erythropoietin: Physico- and Biochemical Analysis, Journal of Chromatography B: BioMedical Applications, (1996), Abstract	
	19	CUMMINGS, M.N. et al., Subcutaneous Erythropoietin Alpha (Eprex) Is More Painful Than Erythropoietin Beta (Recormon), Nephrol Dial Transplant, (1998), p. 817, Vol 13	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper No: 14

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/637,962
				Filing Date	August 11, 2000
				Confirmation Number	8001
				First Named Inventor	Lawrence H. Thompson
				Group Art Unit	1647
				Examiner Name	Regina M. Deberry
Sheet	3	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

	20	FARIS, P.M. et al., The Effects of Recombinant Human Erythropoietin on Perioperative Transfusion Requirements in Patients Having a Major Orthopaedic Operation, The Journal of Bone and Joint Surgery, (1996), pp. 62-72, Vol. 78-A:1	
	21	FAULDS, D. et al., Epoetin (Recombinant Human Erythropoietin) A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Anaemia and the Stimulation of Erythropoiesis, Drugs, (1989), pp. 863-899, Vol. 38:6	
	22	FRENKEN, L.A.M. et al., Assessment of Pain After Subcutaneous Injection of Erythropoietin in Patients Receiving Haemodialysis, BMJ, (1991), p. 288, Vol. 303	
	23	FULTON, B. et al., Mycophenolate Mofetil - A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in Renal Transplantation, Drugs, (1996), pp. 278-298, Vol. 51:2	
	24	HALSTENSON, C.E. et al., Comparative Pharmacokinetics and Pharmacodynamics of Epoetin Alfa and Epoetin Beta, Clin Pharmacol Ther, (1991), pp. 702-712, Vol. 50	
	25	HENDRIKS, M.W.G. et al., Is Recormon® Less Painful Than Eprex® After Subcutaneous Administration?, Pharmaceutisch Weekblad Scientific Edition, (1992), pp. 55-58, Vol. 14:2	
	26	LUDWIG, H., Epoetin in Cancer-Related Anaemia, Nephrol Dial Transplant, (1999), pp. 85-92, Vol. 14:2	
	27	MACDOUGALL, I.C. et al., Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients, J Am Soc Nephrol, (1999), pp. 2392-2395, Vol. 10	
	28	MARKHAM, A. et al., Epoetin Alfa - A Review of its Pharmacodynamic and Pharmocokinetic Properties and Therapeutic Use in Nonrenal Applications, Drugs, pp. 232-254, Vol 49:2	
	29	MILUTINOVIC, S. et al., Chronic Renal Failure: Anaemia, Erythropoietin-Induced Hypertension in Dialyzed Uremics is Influenced by Glycosylation Patterns of the Molecule, Nephrology Dialysis Transplantation, (2001), p. A91, Vol. 16:6, Abstract	
	30	MILUTINOVIC, S. et al., Dialysis: Anaemia and Erythropoietin Treatment, Differences in Glycosylation Structures Have an Important Impact on Potency and Pharmacokinetics of Erythropoietin (EPO) in Dialyzed Uremics, Nephrology Dialysis Transplantation, (2000), p. A156, Vol. 15:9, Abstract	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper No. 14

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/637,962
				Filing Date	August 11, 2000
				Confirmation Number	8001
				First Named Inventor	Lawrence H. Thompson
				Group Art Unit	1647
				Examiner Name	Regina M. Deberry
Sheet	4	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

	31	MILUTINOVIC, S. et al., Dialysis: Complications of Hemodialysis, Efficacy and Pharmacokinetics of Human Erythropoietins in Dialyzed Uremic Patients Depend on Glycosylation Pattern of the Molecule, J Am Soc Nephrol, A1512, (2000), p. 289A, Vol. 11	
	32	MILUTINOVIC, S. et al., Erythropoietin (EPO) Omega Improves Cognitive Functioning and Quality of Life in Dialysis Patients in Comparison to ALFA, J Am Soc Nephrol, (2002), p. 718A, Vol. 13, Abstract	
	33	MILUTINOVIC, S. et al., Once Weekly Erythropoietin Omega Treatment is Safe and as Effective as Twice Weekly Regimen in correcting Anemia of Dialyzed Patients, Nephrology Dialysis Transplantation, M315, (2002), p. 136, Vol. 17, Abstract	
	34	MIYAKE, T. et al., Purification of Human Erythropoietin, The Journal of Biological Chemistry, (1977), pp. 5558-5564, Vol. 252:15	
	35	NIMITZ, M. et al., Identification and Structural Characterization of a Mannose-6-Phosphate Containing Oligomannosidic *N*-Glycan from Human Erythropoietin Secreted by Recombinant BHK-21 Cells, FEBS Letters, (1995), pp. 203-208, Vol. 365	
	36	NIMTZ, M. et al., Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells, Eru. J. Biochem., (1993), pp. 39-56, Vol. 213	
	37	PECES, R. et al., Antibodies Against Recombinant Human Erythropoietin in a Patient with Erythropoietin-Resistant Anemia, The New England Journal of Medicine, (1996), pp. 523-524, Vol. 335:7	
	38	SANS, T. et al., Effectiveness of Very Low Doses of Subcutaneous Recombinant Human Erythropoietin in Facilitating Autologous Blood Donation Before Orthopedic Surgery, Transfusion, (1996), pp. 822-826, Vo. 36:9	
	39	SIKOLE, A. et al., Epoetin Omega for Treatment of Anemia in Maintenance Hemodialysis Patients, Clinical Nephrology, pp. 237-245, Vol. 57	
	40	STORRING, P.L. et al., Epoetin Alfa and Beta Differ in Their Erythropoietin Isoform Compositions and Biological Properties, British Journal of Haematology, (1998), pp. 79-89, Vol. 100	
	41	SYTKOWSKI, A.J. et al., Biological Activity and Structural Stability of N-Deglycosylated Recombinant Human Erythropoietin, Biochemical and Biophysical Research Communications, (1991), pp. 698-704, Vol. 176:2	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper No. 14

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/637,962
				Filing Date	August 11, 2000
				Confirmation Number	8001
				First Named Inventor	Lawrence H. Thompson
				Group Art Unit	1647
				Examiner Name	Regina M. Deberry
Sheet	5	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

	42	TSUDA, E. et al., The Role of Carbohydrate in Recombinant Human Erythropoietin, Eur. J. Biochem., (1990), pp. 405-411, Vol. 188	
	43	VEYS, N. et al., Pain at the Injection Site of Subcutaneously Administered Erythropoietin: Phosphate-Buffered Epoetin Alpha Compared to Citrate-Buffered Epoetin Alpha and Epoetin Beta, Clinical Nephrology, (1998), pp. 41-44, Vol. 49:1	
	44	VEYS, N. et al., Pain at the Injection Site of Subcutaneously Administered Erythropoietin in Maintenance Hemodialysis Patients: A Comparison of Two Brands of Erythropoietin, Am J Nephrol, (1992), pp. 68-72, Vol. 12:68	

Duplicate

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper No. 14

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

RECEIVED

MAR 12 2003

TECH CENTER 1600/2900

OIPE JC58 MAR 07 2003 PATENT & TRADEMARK OFFICE

Complete if Known	
Application Number	09/637,962
Filing Date	August 11, 2000
Confirmation Number	8001
First Named Inventor	Lawrence H. Thompson
Group Art Unit	1647
Examiner Name	Regina M. Deberry
Attorney Docket No.	500731.01 (BXTD 9005)

Sheet 1 of 5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	4,703,008		Lin, F-K	10/27/1987
	2	5,688,679		Powell, J.S.	11/18/1997
	3	5,955,422		Lin, F-K	09/21/1999
	4	2002/0037832	A1	Nielsen et al.	03/28/2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office	Number[4]	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T[6]
	5	EP	0 813 877	A2	SmithKline Beecham Corporation	12/29/1997	
	6	WO	88/00241	A1	Board of Regents of the University of Washington	01/14/1988	
	7	WO	00/24893	A2	AMGEN Inc.	05/04/2000	
	8	WO	00/35475	A2	Ehrenreich, Hannelore	06/22/2000	
	9	WO	01/82952	A2	Action Pharmaceuticals APS	11/08/2001	

Examiner Signature		Date Considered	6/12/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper No. 14

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known	
Application Number	09/637,962
Filing Date	August 11, 2000
Confirmation Number	8001
First Named Inventor	Lawrence H. Thompson
Group Art Unit	1647
Examiner Name	Regina M. Deberry
Attorney Docket No.	500731.01 (BXTD 9005)

Sheet 2 of 5

	10	WO	01/91780	A1	Ortho-McNeil Pharmaceutical, Inc.	12/06/2001

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	11	ACHARYA et al., Effect of Low Dose Recombinant Human Omega Erythropoietin (rHuEPO) on Anaemia in Patients with Hemodialysis, Journal of the Association of Physicians of India, (1995), pp. 539-542, Vol. 43:8	
	12	BIESMA, D.H., Erythropoietin Treatment for Non-Uremic Patients: A Personal View, The Netherlands Journal of Medicine, (1999), pp. 10-15, Vol. 54	
	13	BIESMA, D.H. et al., Lower Homologous Blood Requirement in Autologous Blood Donors After Treatment with Recombinant Human Erythropoietin, The Lancet, (1994), pp. 367-370, Vol. 344	
	14	BREN, A. et al., A Comparison Between Epoetin Omega and Epoetin Alfa in the Correction of Anemia in Hemodialysis Patients: A Prospective, Controlled Crossover Study, Artificial Organs, (2002), pp. 91-97, Vol. 26:2	
	15	BREN, A.F. et al., Experiences with Epoetin Omega and Epoetin Alfa in Hemodialysis Patients, J Am Soc Nephrol, A1813, (2001), p. 352A, Vol. 12	
	16	CANADIAN ERYTHROPOIETIN STUDY GROUP, Association Between Recombinant Human Erythropoietin and Quality of Life and Exercise Capacity of Patients Receiving Haemodialysis, BMJ, (1990), pp. 573-578, Vol. 300	
	17	CASTELLI, G. et al., Detection of Anti-Erythropoietin Antibodies in Haemodialysis Patients Treated with Recombinant Human-Erythropoietin, Pharmacological Research, (2000), pp. 313-318, Vol. 41:3	
	18	CHOI, D. et al., Erythropoietin: Physico- and Biochemical Analysis, Journal of Chromatography B: BioMedical Applications, (1996), Abstract	
	19	CUMMINGS, M.N. et al., Subcutaneous Erythropoietin Alpha (Eprex) Is More Painful Than Erythropoietin Beta (Recormon), Nephrol Dial Transplant, (1998), p. 817, Vol 13	

Examiner Signature	RMDeBy	Date Considered	6/12/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/637,962
				Filing Date	August 11, 2000
				Confirmation Number	8001
				First Named Inventor	Lawrence H. Thompson
				Group Art Unit	1647
				Examiner Name	Regina M. Deberry
Sheet	3	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

	20	FARIS, P.M. et al., The Effects of Recombinant Human Erythropoietin on Perioperative Transfusion Requirements in Patients Having a Major Orthopaedic Operation, The Journal of Bone and Joint Surgery, (1996), pp. 62-72, Vol. 78-A:1	
	21	FAULDS, D. et al., Epoetin (Recombinant Human Erythropoietin) A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Anaemia and the Stimulation of Erythropoiesis, Drugs, (1989), pp. 863-899, Vol. 38:6	
	22	FRENKEN, L.A.M. et al., Assessment of Pain After Subcutaneous Injection of Erythropoietin in Patients Receiving Haemodialysis, BMJ, (1991), p. 288, Vol. 303	
	23	FULTON, B. et al., Mycophenolate Mofetil - A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in Renal Transplantation, Drugs, (1996), pp. 278-298, Vol. 51:2	
	24	HALSTENSON, C.E. et al., Comparative Pharmacokinetics and Pharmacodynamics of Epoetin Alfa and Epoetin Beta, Clin Pharmacol Ther, (1991), pp. 702-712, Vol. 50	
	25	HENDRIKS, M.W.G. et al., Is Recormon® Less Painful Than Eprex® After Subcutaneous Administration?, Pharmaceutisch Weekblad Scientific Edition, (1992), pp. 55-58, Vol. 14:2	
	26	LUDWIG, H., Epoetin in Cancer-Related Anaemia, Nephrol Dial Transplant, (1999), pp. 85-92, Vol. 14:2	
	27	MACDOUGALL, I.C. et al., Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients, J Am Soc Nephrol, (1999), pp. 2392-2395, Vol. 10	
	28	MARKHAM, A. et al., Epoetin Alfa - A Review of its Pharmacodynamic and Pharmocokinetic Properties and Therapeutic Use in Nonrenal Applications, Drugs, pp. 232-254, Vol 49:2	
	29	MILUTINOVIC, S. et al., Chronic Renal Failure: Anaemia, Erythropoietin-Induced Hypertension in Dialyzed Uremics is Influenced by Glycosylation Patterns of the Molecule, Nephrology Dialysis Transplantation, (2001), p. A91, Vol. 16:6, Abstract	
	30	MILUTINOVIC, S. et al., Dialysis: Anaemia and Erythropoietin Treatment, Differences in Glycosylation Structures Have an Important Impact on Potency and Pharmacokinetics of Erythropoietin (EPO) in Dialyzed Uremics, Nephrology Dialysis Transplantation, (2000), p. A156, Vol. 15:9, Abstract	

Examiner Signature		Date Considered	6/12/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/637,962
				Filing Date	August 11, 2000
				Confirmation Number	8001
				First Named Inventor	Lawrence H. Thompson
				Group Art Unit	1647
				Examiner Name	Regina M. Deberry
Sheet	4	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

OIPE JC58 MAR 07 2003 PATENT & TRADEMARK OFFICE

RECEIVED MAR 12 2003 TECH CENTER 1600/2900

	31	MILUTINOVIC, S. et al., Dialysis: Complications of Hemodialysis, Efficacy and Pharmacokinetics of Human Erythropoietins in Dialyzed Uremic Patients Depend on Glycosylation Pattern of the Molecule, J Am Soc Nephrol, A1512, (2000), p. 289A, Vol. 11
	32	MILUTINOVIC, S. et al., Erythropoietin (EPO) Omega Improves Cognitive Functioning and Quality of Life in Dialysis Patients in Comparison to ALFA, J Am Soc Nephrol, (2002), p. 718A, Vol. 13, Abstract
	33	MILUTINOVIC, S. et al., Once Weekly Erythropoietin Omega Treatment is Safe and as Effective as Twice Weekly Regimen in correcting Anemia of Dialyzed Patients, Nephrology Dialysis Transplantation, M315, (2002), p. 136, Vol. 17, Abstract
	34	MIYAKE, T. et al., Purification of Human Erythropoietin, The Journal of Biological Chemistry, (1977), pp. 5558-5564, Vol. 252:15
	35	NIMITZ, M. et al., Identification and Structural Characterization of a Mannose-6-Phosphate Containing Oligomannosidic *N*-Glycan from Human Erythropoietin Secreted by Recombinant BHK-21 Cells, FEBS Letters, (1995), pp. 203-208, Vol. 365
	36	NIMTZ, M. et al., Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells, Eru. J. Biochem., (1993), pp. 39-56, Vol. 213
	37	PECES, R. et al., Antibodies Against Recombinant Human Erythropoietin in a Patient with Erythropoietin-Resistant Anemia, The New England Journal of Medicine, (1996), pp. 523-524, Vol. 335:7
	38	SANS, T. et al., Effectiveness of Very Low Doses of Subcutaneous Recombinant Human Erythropoietin in Facilitating Autologous Blood Donation Before Orthopedic Surgery, Transfusion, (1996), pp. 822-826, Vo. 36:9
	39	SIKOLE, A. et al., Epoetin Omega for Treatment of Anemia in Maintenance Hemodialysis Patients, Clinical Nephrology, pp. 237-245, Vol. 57
	40	STORRING, P.L. et al., Epoetin Alfa and Beta Differ in Their Erythropoietin Isoform Compositions and Biological Properties, British Journal of Haematology, (1998), pp. 79-89, Vol. 100
	41	SYTKOWSKI, A.J. et al., Biological Activity and Structural Stability of N-Deglycosylated Recombinant Human Erythropoietin, Biochemical and Biophysical Research Communications, (1991), pp. 698-704, Vol. 176:2

Examiner Signature	R M Deberry	Date Considered	6/12/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/637,962
				Filing Date	August 11, 2000
				Confirmation Number	8001
				First Named Inventor	Lawrence H. Thompson
				Group Art Unit	1647
				Examiner Name	Regina M. Deberry
Sheet	5	of	5	Attorney Docket No.	500731.01 (BXTD 9005)

RMD	42	TSUDA, E. et al., The Role of Carbohydrate in Recombinant Human Erythropoietin, Eur. J. Biochem., (1990), pp. 405-411, Vol. 188	
	43	VEYS, N. et al., Pain at the Injection Site of Subcutaneously Administered Erythropoietin: Phosphate-Buffered Epoetin Alpha Compared to Citrate-Buffered Epoetin Alpha and Epoetin Beta, Clinical Nephrology, (1998), pp. 41-44, Vol. 49:1	
RMD	44	VEYS, N. et al., Pain at the Injection Site of Subcutaneously Administered Erythropoietin in Maintenance Hemodialysis Patients: A Comparison of Two Brands of Erythropoietin, Am J Nephrol, (1992), pp. 68-72, Vol. 12:68	

Examiner Signature	R.M. Deberry	Date Considered	6/12/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper No: 14